Aerska adds Patrick Schwab to advise on AI strategy
The GSK VP of AI for Science joins its scientific advisory board, guiding AI use across R&D for brain disease medicines.
See the latest news and media coverage for Aerska. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing brain-targeted RNA medicines
aerska.comLast updated
In short: Aerska raised $39 million in a Series A to advance its brain-shuttle RNAi platform.
The GSK VP of AI for Science joins its scientific advisory board, guiding AI use across R&D for brain disease medicines.
She joins from Bicycle Therapeutics and will lead peptide discovery and optimisation efforts for delivering RNAi medicines to the brain
The round was led by EQT Dementia Fund and age1, bringing total raised to $60 million; proceeds advance its brain shuttle RNAi platform, and three directors join the board.
The round is co-led by Age1, Backed VC and Speedinvest, and funds an antibody-oligo conjugate platform using brain shuttles to silence genes behind Alzheimer's and Parkinson's.
Irish biotech Aerska aims to improve delivery of RNAi interference (RNAi) therapeutics across the blood-brain barrier for treating neurological diseases.
DUBLIN and LONDON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today...
DUBLIN and LONDON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today...
Dublin-based Aerska launched on Wednesday with $21 million in seed funding and a technology designed to shuttle RNA interference medicines past the...
Track Aerska and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Aerska and other trending companies.